Download presentation
Presentation is loading. Please wait.
1
Clinical Activity of Alectinib in Advanced RET-Rearranged Non–Small Cell Lung Cancer
Jessica J. Lin, MD, Elizabeth Kennedy, BA, Lecia V. Sequist, MD, MPH, Priscilla K. Brastianos, MD, Kelly E. Goodwin, MSN, Sara Stevens, MSN, Alexandra C. Wanat, BSN, Lisa L. Stober, BSN, Subba R. Digumarthy, MD, Jeffrey A. Engelman, MD, PhD, Alice T. Shaw, MD, PhD, Justin F. Gainor, MD Journal of Thoracic Oncology Volume 11, Issue 11, Pages (November 2016) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions
2
Figure 1 Responses to alectinib. (A) Axial, T1 post–gadolinium magnetic resonance images before alectinib (A1) and after 6 weeks of therapy (A2) in patient 1 with rearranged during transfection gene (RET)-rearranged NSCLC, demonstrating a decrease in size of the intracranial metastases. (B) Axial chest computed tomography (CT) images at baseline (B1) and after 8 weeks of therapy (B2) in patient 2 with kinesin family member 5B gene (KIF5B)-RET, showing a decrease in the number and size of liver lesions. Her hepatic disease had progressed while she was receiving cabozantinib followed by an experimental rearranged during transfection (RET) inhibitor in the context of dose reductions on account of toxicities. (C) Axial chest CT images at baseline (C1) and after 6 weeks of therapy (C2) in patient 3 with coiled coil domain containing 6 gene (CCDC6)-RET, which reveals a decrease in size of the dominant right upper lobe lung mass and an adjacent small peripheral right upper lobe nodule. Postradiation changes are seen. (D) Axial chest CT images at baseline (D1) and after 6 weeks of therapy (D2) in patient 4 with KIF5B-RET, demonstrating disease progression with an increase in bilateral nodularity, septal thickening, and mediastinal mass/lymphadenopathy. The post alectinib scans (D2) were performed without contrast because of the patient’s renal dysfunction. Journal of Thoracic Oncology , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.